XML 38 R28.htm IDEA: XBRL DOCUMENT
v3.22.0.1

REVENUE (Tables) | 3 Months Ended
--- | ---
Jan. 31, 2022
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
| Three Months Ended January 31
| 2022 |  | 2021
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 317 |  |  | $ | 132 |  |  | $ | 188 |  |  | $ | 637 |  |  | $ | 279 |  |  | $ | 124 |  |  | $ | 152 |  |  | $ | 555 |
Europe | 252 |  |  | 98 |  |  | 101 |  |  | 451 |  |  | 245 |  |  | 92 |  |  | 100 |  |  | 437 |
Asia Pacific | 407 |  |  | 129 |  |  | 50 |  |  | 586 |  |  | 399 |  |  | 115 |  |  | 42 |  |  | 556 |
Total | $ | 976 |  |  | $ | 359 |  |  | $ | 339 |  |  | $ | 1,674 |  |  | $ | 923 |  |  | $ | 331 |  |  | $ | 294 |  |  | $ | 1,548 |
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
| Three Months Ended |  |
| January 31 |  |
| 2022 |  | 2021 |  |  |  |
| (in millions) |  |  |  |
Revenue by End Markets |  |  |  |  |  |  |
Pharmaceutical and Biopharmaceutical | $ | 602 |  |  | $ | 521 |  |  |  |  |
Chemical and Energy | 373 |  |  | 328 |  |  |  |  |
Diagnostics and Clinical | 243 |  |  | 216 |  |  |  |  |
Food | 158 |  |  | 162 |  |  |  |  |
Academia and Government | 141 |  |  | 142 |  |  |  |  |
Environmental and Forensics | 157 |  |  | 179 |  |  |  |  |
Total | $ | 1,674 |  |  | $ | 1,548 |  |  |  |  |
Revenue by Type |  |  |  |  |  |  |
Instrumentation | $ | 691 |  |  | $ | 681 |  |  |  |  |
Non-instrumentation and other | 983 |  |  | 867 |  |  |  |  |
Total | $ | 1,674 |  |  | $ | 1,548 |  |  |  |  |
Contract Liabilities and Changes in Balances | The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the three months ended January 31, 2022:
|  | Contract Liabilities
|  | (in millions)
Ending balance as of October 31, 2021 |  | $ | 519 |
Net revenue deferred in the period |  | 220 |
Revenue recognized that was included in the contract liability balance at the beginning of the period |  | (191) |
Change in deferrals from customer cash advances, net of revenue recognized |  | 34 |
Currency translation and other adjustments |  | (6) |
Ending balance as of January 31, 2022 |  | $ | 576 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration